今日药学

2021, v.31(05) 334-338

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

达芦那韦治疗新型冠状病毒的研究进展
Research Progress of Darunavir in the Treatment of COVID-19

任相霖;陈璐;边原;舒永全;龙恩武;何林;闫峻峰;童荣生;
REN Xianglin;CHEN Lu;BIAN Yuan;SHU Yongquan;LONG Enwu;HE Lin;YAN Junfeng;TONG Rongsheng;Personalized Drug Therapy Key Laboratory of Sichuan Province,Department of Pharmacy,Sichuan Academy of Medical Sciences,Sichuan Provincial People's Hospital,Affiliation Hospital of University of Electronic Science and Technology of China;School of Medicine,University of Electronic Science and Technology of China;

摘要(Abstract):

2019年12月,全球范围爆发了新型冠状病毒(SARS-CoV-2)引发的传染性肺炎,由于SARS-CoV-2传染性强且无特效抗病毒药物,导致SARS-CoV-2迅速全球性蔓延,国内外专家积极投身于抗SARS-CoV-2的研究工作。我国李兰娟院士在体外实验中发现达芦那韦能显著抑制SARS-CoV-2复制,有望成为抗SARS-CoV-2的有效药。因此本文拟对达芦那韦的药理作用、药动学特点、合理使用与药学监护要点进行总结,并综述达芦那韦治疗新型冠状病毒的研究进展,以期为常态化防控SARS-CoV-2提供参考。
In December 2019,infectious pneumonia caused by a new type of coronavirus(SARS-CoV-2) broke out global.As SARS-CoV-2 is highly infectious and has no specific antiviral drugs, it has led to the rapid global spread of SARS-CoV-2.Experts at home and abroad are actively engaged in the research work of anti-SARS-CoV-2.Chinese academician Lanjuan Li found experiments that darunavir could significantly inhibit the replication of SARS-CoV-2 in vitro, and it was expected to become an effective drug against SARS-CoV-2.Therefore, this article summarizes the pharmacological effects, pharmacokinetic characteristics, rational use and key points of pharmaceutical care of darunavir, and summarizes the research progress of darunavir in the treatment of SARS-CoV-2 for providing normalized prevention and control of SARS-CoV-2 reference.

关键词(KeyWords): 新型冠状病毒肺炎;新型冠状病毒;达芦那韦;治疗
COVID-19;SARS-CoV-2;darunavir;therapy

Abstract:

Keywords:

基金项目(Foundation): 国家临床重点专科建设项目(30305030698);; 四川省省级公益性科研院所基本科研业务专项课题(2018YSKY0017);; 四川省人民医院院级科研基金临床研究及转化项目(2018LY09);; 四川省科技计划项目(2021YJ0189);; 四川省人民医院个体化药物治疗省重点实验室开放和自拟课题(2018YB06)

作者(Author): 任相霖;陈璐;边原;舒永全;龙恩武;何林;闫峻峰;童荣生;
REN Xianglin;CHEN Lu;BIAN Yuan;SHU Yongquan;LONG Enwu;HE Lin;YAN Junfeng;TONG Rongsheng;Personalized Drug Therapy Key Laboratory of Sichuan Province,Department of Pharmacy,Sichuan Academy of Medical Sciences,Sichuan Provincial People's Hospital,Affiliation Hospital of University of Electronic Science and Technology of China;School of Medicine,University of Electronic Science and Technology of China;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享